Perylene‐Mediated Cytoskeletal Dysfunction Remodels Cancer‐Associated Fibroblasts to Augment Antitumor Immunotherapy
Advanced Healthcare Materials · 2024-04 · 13 (11)
DOI: 10.1002/adhm.202303837 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 15.01.2024. Verfasst von Bing Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for NanoMedical Photonics, School of Basic Medical Science, Henan University, Zhengzhou, Henan, 475001, P. R. China. Hauptthemen laut MEDLINE: Perylene, Cytoskeleton, Cancer-Associated Fibroblasts, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Henan, University of Henan Province.
Abstract (Originalsprache)
Targeted reprogramming of cancer‐associated fibroblasts (CAFs) is one of the most essential cancer therapies. However, how to reprogram active CAFs toward deactivated state still remains immense challenge. To tackle this challenge, herein, one perylene N, N'‐bis(2‐((dimethylammonium)ethylene)‐2‐(methoxylethyl))‐1, 6, 7, 12‐tetrachloroperylene‐3, 4, 9, 10‐tetracarboxylic diimide (PDIC‐OC) is prepared, which can trigger endogenous reactive oxygen species (ROS) burst to result in cytoskeletal dysfunction and cell apoptosis so that suppress transforming growth factor β (TGF‐β) production. As a result, PDIC‐OC can reprogram the activated CAFs and relieve immunosuppressive tumor microenvironment by efficient polarization of M2‐typed macrophages into M1‐typed ones, downregulation of alpha‐smooth muscle actin (α‐SMA), alleviation of hypoxic state to promote infiltration of cytotoxic T lymphocytes, and ultimately realizes outstanding antitumor performance on B16F10 tumor‐xenografted and lung‐metastatic mouse model even at low concentration of 1 mg kg −1 body weight. This work thus presents a novel strategy that cytoskeleton dysfunction and cell apoptosis cooperatively suppress the secretion of TGF‐β to reprogram CAFs and meanwhile clarifies intrinsic mechanism for perylene‐triggered chemo‐immunotherapy against hypoxic tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for NanoMedical Photonics, School of Basic Medical Science, Henan University, Zhengzhou, Henan, 475001, P. R. China.
- Life and Health Intelligent Research Institute, Tianjin Key Laboratory of Life and Health Detection, Tianjin University of Technology, Tianjin, 300387, P. R. China.
ORCID-Profile: Yongwei Huang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Henan
- University of Henan Province
- Animal Management and Ethics Committee of Henan University
- Henan University
Zitieren
APA
Shi, B., Lou, X., Ma, F., Nie, Y., Chen, H., Huang, Y., Zhang, W., & Wang, T. (2024). Perylene‐Mediated Cytoskeletal Dysfunction Remodels Cancer‐Associated Fibroblasts to Augment Antitumor Immunotherapy. Advanced Healthcare Materials, 13(11). https://doi.org/10.1002/adhm.202303837
Vancouver
Shi B, Lou X, Ma F, Nie Y, Chen H, Huang Y, et al. Perylene‐Mediated Cytoskeletal Dysfunction Remodels Cancer‐Associated Fibroblasts to Augment Antitumor Immunotherapy. Advanced Healthcare Materials. 2024;13(11). doi:10.1002/adhm.202303837
BibTeX
@article{Shi2024,
author = {Shi, Bing and Lou, Xue and Ma, Feiyan and Nie, Yanling and Chen, Haoxing and Huang, Yongwei and Zhang, Wei and Wang, Tie},
title = {Perylene‐Mediated Cytoskeletal Dysfunction Remodels Cancer‐Associated Fibroblasts to Augment Antitumor Immunotherapy},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {11},
doi = {10.1002/adhm.202303837}
}
EUVIMED